Tempus AI
In 2014, Liz Lefkofsky was diagnosed with breast cancer. Her husband saw how little data reached her care.
Verdict: Tempus named its patient app after a 19-year-old Lefkofsky couldn't help, and its About page tells no founding story.
A Narrative Authenticity Framework analysis of Tempus AI. NAF score 8.6 out of 10. Weakest component: Real Aspiration, 7.5.
Originally published on LinkedIn, March 30, 2026. Facts checked and updated November 2026.
In 2014, Liz Lefkofsky was diagnosed with breast cancer. Her husband, Eric, spent long hours with her in cancer clinics. He told Forbes he was perplexed by how little data had made its way into her care.
Lefkofsky had already built Groupon. He had no medical training. He founded Tempus in 2015 anyway and, by Forbes' account, funded it early with about $100 million from his own pocket and his venture firm, Lightbank. He said he wasn't sure at first whether it would be a company or a nonprofit.
Years later he tried to use Tempus to help Olivia, a 19-year-old friend of his daughter. She died in the winter of 2021. In a 2024 post on Tempus's blog, Lefkofsky wrote that not being able to help her "broke my heart." He named the company's patient app olivia.
Few founders in the series have put that much of themselves on the record. Tempus's homepage and About page still tell none of it.
Where Tempus stands
The founder. Eric Lefkofsky, founder and CEO since 2015.
The growth. Third-quarter 2026 revenue was $411.5 million, up 23 percent. The data and applications business grew 33 percent. In July 2026, Tempus agreed to buy Personalis, a cancer-monitoring test maker, in a deal valued at about $1.7 billion. It's expected to close in late 2026 or early 2027.
The proof. A $200 million data and model deal with AstraZeneca and Pathos AI in 2025. Total contract value of more than $1.1 billion at the end of 2025. A data deal with BMS in October 2026, which the company says brought data licensing bookings past $550 million for the year.
The brand line. The homepage opens with "Welcome to the future of healthcare." The About page says "Redefining the future of precision medicine." An older mission line, still in Tempus's company descriptions, was sharper: for each patient to benefit from the treatment of others who came before.
The NAF scorecard
| Component | Score | One-line read |
|---|---|---|
| Friction | 9.0 | Cancer care that ignores data the system already has |
| Lived Stake | 9.5 | A husband in the clinic, then a young friend he couldn't help |
| Distinctive Qualification | 8.5 | A decade of linked data, now paid for by drugmakers |
| Real Aspiration | 7.5 | "The future of healthcare," which any rival could say |
| Composite | 8.6 |
Scores as of publication. Current standings at seekargus.com/leaderboard.
Tempus ties Sword Health for second in the series. Patagonia's 9.5 is the reference point. The scores hold from the original article.
Friction: 9.0
The problem is specific and costly. A tumor can be sequenced and compared with many past cases, yet that knowledge often doesn't reach the doctor making the treatment call. Lefkofsky saw the gap from the chair next to his wife.
It stops short of 9.5 because Tempus states this most clearly in Lefkofsky's own posts and interviews. The company's front pages talk about the future instead of the problem.
Lived Stake: 9.5
Lefkofsky lived the problem as a family member, one step removed from being the patient. That's the only reason this isn't a 10. He also put his own money in before outside investors did, and he's still CEO eleven years later.
The Olivia story adds something rare: a founder saying in public that his platform fell short for someone he cared about, then building a product in her name.
Distinctive Qualification: 8.5
Tempus has spent a decade linking genetic test results to clinical records, and drugmakers now pay real money for that data. The AstraZeneca and BMS deals are outside proof that the data is worth building on. The Personalis deal adds tests that track cancer after treatment, which feeds more data back in.
Two things hold the score at 8.5. Rivals such as Foundation Medicine and Guardant Health hold large data sets of their own. And part of Tempus's data revenue comes from Pathos AI, which its filings list as a related party.
Real Aspiration: 7.5
"Welcome to the future of healthcare" could open any health tech site. The older line, each patient benefiting from those who came before, describes a real change and how it happens. It has slipped out of the front pages.
A 9 would put that line back at the top and make it concrete: a patient at a community hospital gets treatment informed by everyone who came before, the same as a patient at a top cancer center.
The story Tempus should tell
When my wife was diagnosed with cancer, I couldn't believe how little of what medicine knew reached her care. We built Tempus so every patient benefits from the patients who came before. We named our patient app after Olivia, because we couldn't help her, and we're still building for the next one.
Three moves to raise the score
1. Put the founding story on the About page (Friction 9.0 to 9.5)
Add a short founder section to tempus.com/about-us: Liz's diagnosis in 2014, what Lefkofsky saw in the clinic, and why he built Tempus. Link to the Olivia post. Measure it by time on the About page and by how often press coverage repeats the story.
Prior-work check: Partial. Tempus published "Meet Olivia" on its blog in September 2024, and Lefkofsky's personal site carries the story. The About page lists him as founder and CEO but has no founding story, as of November 19, 2026.
2. Bring back the "patients who came before" line (Real Aspiration 7.5 to 8.5)
Replace "Welcome to the future of healthcare" on the homepage with the mission Tempus already wrote: each patient benefits from the treatment of others who came before. Add one line on what that means at a community hospital. Measure it by how often analysts, press and partners use the line.
Prior-work check: Partial. The line appears in Tempus's older company descriptions, including its Glassdoor company profile. It isn't on the homepage or About page, as of November 19, 2026.
3. Publish plain-language stories of changed treatment (Distinctive Qualification 8.5 to 9.0)
With consent, document cases where Tempus data changed a treatment decision, and what happened next, written for patients and doctors. Investors get earnings calls. Patients get nothing comparable. Measure it by physician sign-ups that cite the series and by readership among patients using olivia.
Prior-work check: Partial. Tempus posts clinical case reports for physicians on its resources pages. No patient-facing series on changed treatment decisions found, as of November 19, 2026.
| Move | Closest existing program | Status |
|---|---|---|
| Founding story on the About page | "Meet Olivia" blog post, 2024 | Partial |
| "Patients who came before" on the homepage | Older company descriptions | Partial |
| Patient-facing treatment stories | Physician case reports | Partial |
Projected composite: 9.1 (Friction 9.5, Lived Stake 9.5, Distinctive Qualification 9.0, Real Aspiration 8.5). These checks cover public sources only and can't see Tempus's internal plans.
Sources
- Forbes: Lefkofsky's wife's diagnosis and the early $100 million
- Tempus blog: "Meet olivia," by Eric Lefkofsky, September 2024
- Tempus homepage and About page, viewed November 19, 2026
- Tempus: AstraZeneca and Pathos agreements, April 2025
- Tempus 8-K: total contract value above $1.1 billion, January 2026
- Tempus to acquire Personalis, July 20, 2026
- Tempus third-quarter 2026 results, November 2, 2026
Tim Donovan · SeekArgus